Unspecified degradation impurities identification and characterization in bilastine and montelukast tablet formulations by using UPLC and LCMS/MS: Robustness by design expert and green assessment
Annales Pharmaceutiques Françaises · 2025-11 · 83 (6) · 1092-1113
DOI: 10.1016/j.pharma.2025.04.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annales Pharmaceutiques Françaises, 2025-11. Verfasst von Raj Kumar Kodishala und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Koneru Lakshmaiah Education Foundation, Aziznagar, Hyderabad, Telangana 500075, India. Hauptthemen laut MEDLINE: Quinolines, Drug Contamination, Acetates, Piperidines. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: This study introduces a novel ultra-performance liquid chromatography (UPLC) method for the rapid, simple, and accurate detection of contaminants in bilastine (BLS) and montelukast (MTK) tablet formulations. MATERIAL AND METHODS: The separation of BLS impurity-A, BLS impurity-B, BLS, MTK impurity-A, MTK, and MTK impurity-B was achieved using an Acquity BEH C18 column (50×2.1mm, 1.7μm) under gradient eluent conditions. The mobile phases consisted of 0.1% triethylamine in water with the pH adjusted to 2.5 using orthophosphoric acid (mobile phase A) and acetonitrile (mobile phase B). The ratio of mobile phase A to B was 70:30 (v/v). The column flow rate was set at 0.2mL/min, and the photodiode array detector (PDA) was used to quantify the analytes. The detection wavelength was set to 224nm. RESULTS: In a runtime of just 20minutes, 13 analytes were successfully separated. The retention times for the target compounds and impurities were as follows: BLS impurity-A: 1509min, BLS impurity-B: 3435min, BLS: 5668min, MTK impurity-A: 8137min, MTK: 9784min, MTK impurity-B: 11,853min. The unspecified impurities in the degradation samples were detected at retention times of 2174, 2657, 3368, 4143, 8239, 11,722, and 12,436minutes, and were characterized using liquid chromatography-mass spectrometry (LC-MS). CONCLUSION: The UPLC-based analytical method demonstrated in this study is an effective and efficient technique for the quantification of BLS, MTK, and their associated impurities in tablet formulations. This method has been validated in accordance with ICH Q2(R2) and USP guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Koneru Lakshmaiah Education Foundation, Aziznagar, Hyderabad, Telangana 500075, India.
- GITAM Deemed to be University, Department of Chemistry, School of Science, Hyderabad, Telangana 502329, India.
- Department of Chemistry, Koneru Lakshmaiah Education Foundation, Aziznagar, Hyderabad, Telangana 500075, India. Electronic address: sreedhar.gundekari@gmail.com.
Zitieren
APA
Kodishala, R. K., Sayyad, K., Kowtharapu, L. P., Konduru, N., Mondal, T., Varkolu, M., & Gundekari, S. (2025). Unspecified degradation impurities identification and characterization in bilastine and montelukast tablet formulations by using UPLC and LCMS/MS: Robustness by design expert and green assessment. Annales Pharmaceutiques Françaises, 83(6), 1092-1113. https://doi.org/10.1016/j.pharma.2025.04.006
Vancouver
Kodishala RK, Sayyad K, Kowtharapu LP, Konduru N, Mondal T, Varkolu M, et al. Unspecified degradation impurities identification and characterization in bilastine and montelukast tablet formulations by using UPLC and LCMS/MS: Robustness by design expert and green assessment. Annales Pharmaceutiques Françaises. 2025;83(6):1092-1113. doi:10.1016/j.pharma.2025.04.006
BibTeX
@article{Kodishala2025,
author = {Kodishala, Raj Kumar and Sayyad, Kousrali and Kowtharapu, Leela Prasad and Konduru, Naresh and Mondal, Tanmoy and Varkolu, Mohan and Gundekari, Sreedhar},
title = {Unspecified degradation impurities identification and characterization in bilastine and montelukast tablet formulations by using UPLC and LCMS/MS: Robustness by design expert and green assessment},
journal = {Annales Pharmaceutiques Françaises},
year = {2025},
volume = {83},
number = {6},
pages = {1092--1113},
doi = {10.1016/j.pharma.2025.04.006}
}
EUVIMED